Patents by Inventor Thomas Gelbrich

Thomas Gelbrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Co-Crystals Comprising Levothyroxine And A Dicarboxylic Acid
    Publication number: 20210395186
    Abstract: The present invention relates to co-crystals comprising levothyroxine and a dicarboxylic acid, preferably L-tartaric acid or oxalic acid, and processes for the preparation thereof. Furthermore, the invention relates to a pharmaceutical composition comprising a co-crystal of the present invention, preferably the co-crystal comprising levothyroxine and L-tartaric acid or oxalic acid, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypothyroidism.
    Type: Application
    Filed: October 16, 2019
    Publication date: December 23, 2021
    Applicant: Sandoz AG
    Inventors: Marijan Stefinovic, Dennis Dimo Enkelmann, Ulrich Griesser, Thomas Gelbrich
  • Co-crystal of an orally available HIF prolyl hydroxylase inhibitor
    Patent number: 11192860
    Abstract: The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 7, 2021
    Inventors: Hannes Lengauer, Arthur Pichler, Renate Margreiter, Thomas Gelbrich
  • Co-Crystal of an Orally Available Hif Prolyl Hydroxylase Inhibitor
    Publication number: 20200262792
    Abstract: The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).
    Type: Application
    Filed: July 11, 2018
    Publication date: August 20, 2020
    Applicant: Sandoz AG
    Inventors: Hannes Lengauer, Arthur Pichler, Renate Margreiter, Thomas Gelbrich